Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Официальное название

A Phase Two Study of Venetoclax Plus Zanubrutinib in Newly Diagnosed CLL and After Front-Line Time-Limited Venetoclax-Based Therapy

Обзор

This phase II trial tests the effect of venetoclax in combination with standard of care (SOC) zanubrutinib in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Zanubrutinib blocks a protein called Bruton tyrosine kinase (BTK), which may help keep cancer cells from growing. It is a type of tyrosine kinase inhibitor. Giving venetoclax in combination with SOC zanubrutinib may be safe and tolerable and may reduce the number of cancer cells that remain in the body in patients with CLL or SLL that have not previously received treatment or at least two years have passed since completing initial treatment.

Подробное описание

PRIMARY OBJECTIVE:

I. To determine undetectable minimal residual disease (uMRD) rates in CLL patients receiving fixed-duration combined treatment with venetoclax plus zanubrutinib.

SECONDARY OBJECTIVES:

I. Overall response rate. (Frontline Cohort) II. Rate of complete remission. (Frontline Cohort) III. Duration of response. (Frontline Cohort) IV. Duration of uMRD if achieved. (Frontline Cohort) V. Time to next treatment. (Frontline Cohort) VI. Rate of adverse events with zanubrutinib and venetoclax treatment. (Frontline Cohort) VII. Overall response rate. (Second Line Cohort) VIII. Rate of complete remission. (Second Line Cohort) IX. Rate of uMRD at cycle 15 of treatment. (Second Line Cohort) X. Duration of response. (Second Line Cohort) XI. Duration of uMRD if achieved. (Second Line Cohort) XII. Time to next treatment. (Second Line Cohort) XIII. Rate of adverse events with zanubrutinib and venetoclax treatment. (Second Line Cohort)

EXPLORATORY OBJECTIVES:

I. Estimated 36-months progression-free survival. II. Progression-free survival for both cohorts. III. Overall survival for both cohorts. IV. Patient and disease characteristics associated with achieving uMRD status. V. Development of resistance mutations associated with BTK inhibitor (BTKi) and venetoclax.

VI. BH3 profiling at baseline and after cycle (C)3 of treatment with zanubrutinib.

VII. Impact of treatment on measures of immune function. VIII. Incidence of laboratory and clinical tumor lysis syndrome (TLS) during venetoclax ramp-up, change in TLS risk category after zanubrutinib lead-in (C1-3), and interventions for electrolyte changes.

OUTLINE: Patients who have not previously been treated are assigned to Cohort I and patients who completed initial treatment are assigned to Cohort II.

COHORT I (FRONTLINE COHORT): Patients receive SOC zanubrutinib orally (PO) once daily (QD) or twice daily (BID) per physician discretion on days 1-28 of each cycle. Starting with cycle 4, patients also receive venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 15 cycles in the absence of disease progression or unacceptable toxicity.

COHORT II (SECOND LINE COHORT): Patients receive SOC zanubrutinib PO QD or BID per physician discretion on days 1-28 of each cycle. Starting with cycle 4, patients also receive venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 27 cycles in the absence of disease progression or unacceptable toxicity.

Additionally, patients undergo blood sample collection, bone marrow biopsy and aspiration, and computed tomography (CT) or magnetic resonance imaging (MRI) throughout the study.

After completion of study treatment, patients are followed up at 28 days, every 12 weeks (3 months) up to progression then every 6 months for up to year 5.

Вмешательства

• Процедура Biospecimen Collection
  Undergo blood sample collection
• Процедура Bone Marrow Aspiration
  Undergo bone marrow biopsy and aspiration
• Процедура Bone Marrow Biopsy
  Undergo bone marrow biopsy and aspiration
• Процедура Computed Tomography
  Undergo CT
• Процедура Magnetic Resonance Imaging
  Undergo MRI
• Препарат Venetoclax
  Given PO
• Препарат Zanubrutinib
  Given PO

Первичные конечные точки

• Rate of undetectable minimal residual disease (uMRD) (Firstline Cohort) [Срок оценки: At end of cycle 15 (cycle length = 28 days)]
• Rate of uMRD (Second Line Cohort) [Срок оценки: At end of cycle 27 (cycle length = 28 days)]

Вторичные конечные точки (12)

• Overall response rate (Frontline Cohort) [Срок оценки: Up to 5 years]
• Rate of complete remission (Frontline Cohort) [Срок оценки: Up to 5 years]
• Duration of clinical response (Frontline Cohort) [Срок оценки: From date of achieving response to progression or death, assessed up to 5 years]
• Duration of uMRD if achieved (Frontline Cohort) [Срок оценки: From date of achieving uMRD to progression or death, assessed up to 5 years]
• Time to next treatment (Frontline Cohort) [Срок оценки: From date of treatment start to the start date of the next treatment, assessed up to 5 years]
• Rate of adverse events (AEs) (Frontline Cohort) [Срок оценки: Up to 28 days after last dose of study treatment]
• Overall response rate (Second Line Cohort) [Срок оценки: Up to 5 years]
• Rate of complete remission (Second Line Cohort) [Срок оценки: Up to 5 years]
• Rate of uMRD (Second Line Cohort) [Срок оценки: At cycle 15 of treatment (cycle length = 28 days)]
• Duration of clinical response (Second Line Cohort) [Срок оценки: From date of achieving response to progression or death, assessed up to 5 years]
• Duration of uMRD if achieved (Second Line Cohort) [Срок оценки: From date of achieving uMRD to progression or death, assessed up to 5 years]
• Time to next treatment (Second Line Cohort) [Срок оценки: From date of treatment start to the start date of the next treatment, assessed up to 5 years]

Критерии участия

Критерии включения

• Diagnosis of CLL/SLL meeting criteria established in International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 criteria
• Age ≥ 18 years
• Indications for treatment as defined by the iwCLL 2018 Guidelines
• Received prior treatment or not depending on cohort

• Frontline cohort:

• CLL/SLL who are treatment-naïve and have met criteria 1 through 3 above
• Second line cohort:

• Must have received time-limited venetoclax based therapy in the front line. This is defined as treatment with venetoclax and an-anti-CD20 antibody, venetoclax and a BTKi, or treatment with venetoclax and a BTKi, and an anti-CD20 monoclonal antibody that was given for a fixed-duration. Patients who discontinue ibrutinib, due to intolerance, in a BTKi and venetoclax +/- obinutuzumab combination are eligible provided they completed other drugs in the regimen and in the opinion of the treating investigator the intolerance will not limit treatment with zanubrutinib and venetoclax. Patients who discontinued BTKi other than ibrutinib or who discontinued venetoclax due to intolerance will be excluded
• At least 2 years since completion of initial CLL treatment
• Only 1 prior line of therapy. Treatment with rituximab or other anti-CD20 monoclonal antibody for idiopathic thrombocytopenic purpura (ITP) or autoimmune hemolytic anemia (AIHA) is not considered a prior line of CLL/SLL therapy
• Eastern Cooperative Oncology Group (ECOG) performance 0-2
• Absolute neutrophil count (ANC) > 1000/mm\^3 (independent of growth factor support at screening, unless cytopenias are due to marrow involvement by CLL/SLL)
• Platelets > 30,000/mm\^3 at screening (independent of growth factor support at screening, unless cytopenias are due to marrow involvement by CLL/SLL)
• Hemoglobin > 7 g/dL (independent of growth factor support at screening, unless cytopenias are due to marrow involvement by CLL/SLL)
• Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 3 x the upper limit of normal (ULN) or ≤ 5 x ULN with documented liver involvement
• Bilirubin ≤ 1.5 x ULN or ≤ 3 x ULN with documented liver involvement and/or Gilbert's disease
• Creatinine clearance (CrCl) ≥ 50 according to modified Cockcroft-Gault equation
• Willing and able to complete study activities and treatment
• Willing and capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol
• Willingness of men and women of reproductive potential and their partners to observe conventional and highly effective or acceptable birth control methods for the duration of treatment and for 1 week following the last dose of zanubrutinib or 30 days following the last dose of venetoclax, whichever is longer

Критерии исключения

• Second line arm only: Patients who progressed per iwCLL 2018 criteria on therapy or within two years of completing time-limited, venetoclax based treatment
• Frontline arm only: Patients with deletion 17p and/or TP53 mutation
• Active Richter's transformation
• Prior zanubrutinib exposure
• Known hypersensitivity to any of the excipients of zanubrutinib or venetoclax
• Need for treatment with warfarin or other vitamin K antagonist during study treatment
• History of stroke or intracranial hemorrhage within 6 months
• Known bleeding diathesis
• Inability to take pills or oral medications
• Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption of either zanubrutinib or venetoclax
• Active second malignancy unless in remission and with life expectancy > 2 years. Adjuvant endocrine therapy for breast or prostate cancer that is expected to be cured is allowed. Non-melanoma skin cancers are permitted if adequately treated
• Psychiatric illness, or social situations that would limit compliance with study requirements
• Active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia \[AIHA\], idiopathic thrombocytopenic purpura \[ITP\]) for which new therapy was introduced or existing therapy was escalated within the 4 weeks prior to study enrollment to maintain adequate blood counts
• Evidence of other clinically significant uncontrolled condition(s) including but not limited to, uncontrolled systemic bacterial, viral, fungal or parasitic infection (except for fungal nail infection), or other clinically significant active disease process which in the opinion of the investigator may pose a risk for patient participation. Screening for chronic conditions is not required
• Significant cardiovascular disease defined as:

• Unstable angina or acute coronary syndrome within the past 2 months
• History of myocardial infarction within 3 months
• Documented left ventricular ejection fraction (LVEF) by any method of ≤ 40% within 12 months
• ≥ grade 3 New York Heart Association (NYHA) functional classification system of heart failure
• Uncontrolled or symptomatic arrhythmias

• Note: Patients with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker
• Prolongation of the QT interval corrected for heart rate (QTcF) > 470 msec. QTcF is calculated using Fridericia's Formula (QTcF)

• Correction of suspected drug induced QTcF prolongation can be attempted at the investigator's discretion and only if clinically safe to do so with either discontinuation of the offending drug or switch to another drug not known to be associated with QTcF prolongation
• Correction for underlying bundle branch block (BBB) allowed
• Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection based on criteria below:

• Hepatitis B virus (HBV): Patients with positive hepatitis B surface antibody (HBsAb) are not excluded. Patients with positive hepatitis B core antibody (anti-HBc) and negative HBsAg require hepatitis B polymerase chain reaction (PCR) evaluation before inclusion. Patients who are hepatitis B PCR positive at time of screening will be excluded. Those who have hepatitis B core antibody positive and a negative PCR will be included if they are agreeable to receive antiviral prophylaxis
• Hepatitis C virus (HCV): If hepatitis C antibody is positive, patients will need to have a negative result for hepatitis C ribonucleic acid (RNA) before inclusion. Patients who are hepatitis C RNA positive at time of screening will be excluded. Patients previously treated for hepatitis C > 6 months previously with a negative RNA test are eligible
• Patients who are receiving intravenous immunoglobulin (IVIG) who test positive for any hepatitis B or C serologies and have a negative PCR and who are deemed likely to have received antibodies passively through IVIG and not from prior infection will be included without viral prophylaxis
• Treatment with a strong cytochrome P450 (CYP)3A inhibitor or inducer and/or strong P-glycoprotein (P-gp) inhibitors within 3 days of starting and during study treatment
• Patients may not plan to consume grapefruit or grapefruit products, Seville oranges or products from Seville oranges, or star fruit
• Pregnancy, lactation, or plan to breastfeed during treatment with or within 2 weeks of the last dose of zanubrutinib or 1 month of the last dose of venetoclax
• Major surgery within 4 weeks prior to screening
• Vaccination with live vaccine within 28 days of screening
• Currently incarcerated
• Current central nervous system involvement by CLL/SLL

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Нерандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

США · 1 центр

• Ohio State University Comprehensive Cancer Center — Columbus

Идентификаторы

NCT: NCT07734038 · OSU-25150 · NCI-2026-05223 · STUDY20251617

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗